An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Latest Information Update: 12 Dec 2023
At a glance
- Drugs Inclisiran (Primary) ; Evolocumab
- Indications Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- Acronyms ORION-3
- Sponsors Novartis Pharmaceuticals; The Medicines Company
- 12 Dec 2023 Results of post hoc analysis assessing the safety and tolerability of inclisiran for treatment of hypercholesterolemia from completed (ORION-1, -3, -5, -9, -10, and -11) and ongoing (ORION-8) trials, published in the Journal of the American College of Cardiology.
- 07 Nov 2022 Results published in the Novartis Media Release.
- 07 Nov 2022 According to a Novartis media release, results from the study were presented at the American Heart Association (AHA) Scientific Sessions 2022.